MICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa study
Lead Research Organisation:
Newcastle University
Department Name: Translational and Clinical Res Institute
Abstract
Context
Rheumatoid arthritis (RA) is a condition in which the joints become inflamed and painful. It affects about 1 in every 100 adults in the UK. It is thought to be caused by the patient's immune system mistakenly attacking their joints. The resulting inflammation is not only painful but reduces joint movement and eventually causes joint damage and deformity. RA can also affect other organs such as the lungs, and patients with RA also have a higher than average risk of developing heart attacks and strokes. They are also more susceptible to infections. Many patients lose their jobs soon after the diagnosis is made.
Aims and objectives
Most drugs currently used to treat RA neutralise the inflammation (anti-inflammatory drugs, steroids) or the cells of the immune system and their products (biological therapies or 'magic bullets'). Over the past 20 years the outcome for RA patients has improved, partly because of earlier and more 'aggressive' treatment (more drugs, higher doses) and partly because of new therapies that have been developed (particularly the 'magic bullets'). However, many patients don't respond completely to these treatments and some don't respond at all. We believe that there is another type of cell responsible for the symptoms in these patients. The fibroblast is a cell that is present in healthy joints, where it is important for normal joint function. However, fibroblasts divide inappropriately and become more numerous and 'aggressive' in RA joints. They damage the joint by producing chemicals that eat into cartilage and bone, and also produce inflammatory chemicals themselves.
Thus, a useful cell in health becomes one that causes inflammation and joint damage in RA. As far as we know none of the current treatments affect the behaviour of fibroblasts. Our plan is test a drug in RA patients that we think will do so. The drug interferes with the machinery that is necessary for cells to divide. Fibroblasts in the RA joint seem particularly sensitive to this drug, which we therefore believe can correct their abnormal behaviour. The drug has already been tested in patients with certain types of cancer (in which cells also divide inappropriately) and seems safe enough to test in RA. We aim to show that the treatment is safe in RA, and that it could provide a useful treatment for RA patients.
The research is divided into two parts. In the first part we will test the safety of different doses of the drug over 4 weeks of treatment. We will identify a dose that is both safe and appropriate to test in more patients for a longer period of time. In the second part we will give this dose to 12 RA patients for 12 weeks. At the same time 6 patients will receive an identical 'placebo' treatment. This is important to ensure that any effects we see are due to the drug and not other factors (more visits to the hospital, more interaction with doctors and nurses). As well as checking the patients' symptoms, we will also perform scans of their joints at the start and end of the treatment. We will also take small samples of joint tissue (biopsies). These scans and biopsies will help us to decide whether the treatment is working and how it is working. This is important to help us to decide whether the trial has been a 'success' and whether to perform further trials later on.
Potential applications and benefit
In this trial we will treat patients who have had RA for at least a year and who are already taking treatment but not responding well enough. This will test our idea that we can improve their symptoms by altering the behaviour of the fibroblasts. If this research is successful then we will need to test the treatment in RA patients taking different treatments, at different stages of their illness. Because this treatment works in such a different way to existing drugs, we believe it could be useful for many different types of RA patient. Later on, if safe and effective, it may also be useful in other diseases.
Rheumatoid arthritis (RA) is a condition in which the joints become inflamed and painful. It affects about 1 in every 100 adults in the UK. It is thought to be caused by the patient's immune system mistakenly attacking their joints. The resulting inflammation is not only painful but reduces joint movement and eventually causes joint damage and deformity. RA can also affect other organs such as the lungs, and patients with RA also have a higher than average risk of developing heart attacks and strokes. They are also more susceptible to infections. Many patients lose their jobs soon after the diagnosis is made.
Aims and objectives
Most drugs currently used to treat RA neutralise the inflammation (anti-inflammatory drugs, steroids) or the cells of the immune system and their products (biological therapies or 'magic bullets'). Over the past 20 years the outcome for RA patients has improved, partly because of earlier and more 'aggressive' treatment (more drugs, higher doses) and partly because of new therapies that have been developed (particularly the 'magic bullets'). However, many patients don't respond completely to these treatments and some don't respond at all. We believe that there is another type of cell responsible for the symptoms in these patients. The fibroblast is a cell that is present in healthy joints, where it is important for normal joint function. However, fibroblasts divide inappropriately and become more numerous and 'aggressive' in RA joints. They damage the joint by producing chemicals that eat into cartilage and bone, and also produce inflammatory chemicals themselves.
Thus, a useful cell in health becomes one that causes inflammation and joint damage in RA. As far as we know none of the current treatments affect the behaviour of fibroblasts. Our plan is test a drug in RA patients that we think will do so. The drug interferes with the machinery that is necessary for cells to divide. Fibroblasts in the RA joint seem particularly sensitive to this drug, which we therefore believe can correct their abnormal behaviour. The drug has already been tested in patients with certain types of cancer (in which cells also divide inappropriately) and seems safe enough to test in RA. We aim to show that the treatment is safe in RA, and that it could provide a useful treatment for RA patients.
The research is divided into two parts. In the first part we will test the safety of different doses of the drug over 4 weeks of treatment. We will identify a dose that is both safe and appropriate to test in more patients for a longer period of time. In the second part we will give this dose to 12 RA patients for 12 weeks. At the same time 6 patients will receive an identical 'placebo' treatment. This is important to ensure that any effects we see are due to the drug and not other factors (more visits to the hospital, more interaction with doctors and nurses). As well as checking the patients' symptoms, we will also perform scans of their joints at the start and end of the treatment. We will also take small samples of joint tissue (biopsies). These scans and biopsies will help us to decide whether the treatment is working and how it is working. This is important to help us to decide whether the trial has been a 'success' and whether to perform further trials later on.
Potential applications and benefit
In this trial we will treat patients who have had RA for at least a year and who are already taking treatment but not responding well enough. This will test our idea that we can improve their symptoms by altering the behaviour of the fibroblasts. If this research is successful then we will need to test the treatment in RA patients taking different treatments, at different stages of their illness. Because this treatment works in such a different way to existing drugs, we believe it could be useful for many different types of RA patient. Later on, if safe and effective, it may also be useful in other diseases.
Technical Summary
This project aims to repurpose a small molecule anti-cancer drug as an anti-fibroblast drug for RA. The past 20 years have seen major advances in RA therapy; more aggressive use of conventional drugs, and biological targeted therapies have each made a significant impact. However, disease remission remains uncommon and around 20% of patients remain refractory to all therapies. This represents a significant unmet need and suggests key aspects of RA pathogenesis remain untargetted.
In health, a delicate nutritive synovial membrane (SM) lines joint cavities. This comprises a few macrophages and fibroblasts in a loose connective tissue stroma. In RA the SM is the focus of autoimmune attack but, in addition to inflammatory cell infiltration, resident synovial fibroblasts (SF) become hyperplastic, forming a vascularised, inflammatory, quasi-malignant pannus which invades articular cartilage and bone. The resultant joint damage underlies the disability and reduced quality of life that characterise RA.
Cell proliferation relies on the coordinated activation of specific regulatory proteins: orderly progression through the cell cycle is tightly controlled by the formation and activation of complexes comprising cyclin proteins and cyclin-dependent kinases (CDK). These complexes are in turn regulated by endogenous CDK inhibitors (CDKI). The concept of inhibiting CDKs to correct uncontrolled cell proliferation has led to the evaluation of small molecule CDKI in cancer.
RA SF have reduced endogenous CDKI levels, and correction of the deficit normalises their dysregulated phenotype. Indeed, small molecule CDKI ameliorate synovitis in pre-clinical arthritis models. In partnership with the SME Cyclacel, we propose a phase IIa repurposing study of a CDKI in patients with refractory RA. Stage 1 will focus on safety and tolerability, to determine an appropriate dose to progress to stage 2, where we will seek evidence of potential therapeutic activity alongside PK and PD biomarkers.
In health, a delicate nutritive synovial membrane (SM) lines joint cavities. This comprises a few macrophages and fibroblasts in a loose connective tissue stroma. In RA the SM is the focus of autoimmune attack but, in addition to inflammatory cell infiltration, resident synovial fibroblasts (SF) become hyperplastic, forming a vascularised, inflammatory, quasi-malignant pannus which invades articular cartilage and bone. The resultant joint damage underlies the disability and reduced quality of life that characterise RA.
Cell proliferation relies on the coordinated activation of specific regulatory proteins: orderly progression through the cell cycle is tightly controlled by the formation and activation of complexes comprising cyclin proteins and cyclin-dependent kinases (CDK). These complexes are in turn regulated by endogenous CDK inhibitors (CDKI). The concept of inhibiting CDKs to correct uncontrolled cell proliferation has led to the evaluation of small molecule CDKI in cancer.
RA SF have reduced endogenous CDKI levels, and correction of the deficit normalises their dysregulated phenotype. Indeed, small molecule CDKI ameliorate synovitis in pre-clinical arthritis models. In partnership with the SME Cyclacel, we propose a phase IIa repurposing study of a CDKI in patients with refractory RA. Stage 1 will focus on safety and tolerability, to determine an appropriate dose to progress to stage 2, where we will seek evidence of potential therapeutic activity alongside PK and PD biomarkers.
Planned Impact
Our research aims to deliver a new drug and a novel therapeutic approach, therefore potential beneficiaries include patients, the NHS, the life sciences industry, UK plc, Arthritis Research UK and other funders, the project team and other academic researchers.
Patients with RA will derive the most immediate impact from our research, which could provide a novel therapy with a unique mechanism of action. This could result in better disease control, improved quality of life and reduced long-term complications, either as a monotherapy or in combination with existing drugs. Success will also stimulate research into related compounds from the same class as well as alternative anti-fibroblast drugs and targets (eg pro-apoptosis, epigenetic modifiers, anti-proliferative). It will also stimulate research into potential applications in other fibrotic diseases - all with potential downstream beneficial impact on patients. Via our Engagement programmes this work will have a wider impact on patients by reinforcing the benefits of participating in early phase experimental medicine research.
For similar reasons success will provide a boost to the UK life sciences industry. Clearly our Partner would benefit greatly but so too will other SMEs, biotechs, and pharma with alternative drugs from the same class, as well as drugs with the potential to target the fibroblast in a distinct manner. Our research would provide a novel target and a novel paradigm for the treatment of RA and would also trigger a re-analysis of exisiting compounds that may have therapeutic potential in RA or, indeed, other fibrotic diseases. RA remains a disease with a high unmet need and provides potentially high investment returns. Some of the other potential disease targets could become 'orphan' indications, with a more commercially favourable path to the clinic.
Downstream success will lead to a workforce with an improved skill set, including UK/EU contract manufacturing capabilities, and specialist PK testing. Ultimately successful development of a novel drug for RA will deliver substantial revenue to the UK and catalyse additional activity in the healthcare sector. It will also impact on HM Government by reinforcing the benefits of their investment in the life sciences industry.
We are using UK based companies for sub-contracted work. This will have a positive impact on income generated and jobs protected within home countries.
Because our research involves an orally available drug, it would likely be cheaper than the biologic drugs. If it substituted for them in the treatment pathway, or improved their efficacy as hypothesised, this would ultimately result in direct or indirect cost-savings to the NHS.
In addition to the MRC, Arthritis Research UK, NIHR, the Wellcome Trust, the partner Universities and NHS Trusts will benefit from our research, because they are providing some of the infrastructure and staff needed to perform this research. They would therefore be in a position to share in the success. The development of a new drug for RA would likely lead to an increase in charitable donations to relevant charities.
Success will impact on the project team both directly, via the experience and educational opportunities of performing a successful phase II experimental medicine study; and also indirectly from the emotional and psychological benefits of involvement with a study that could potentially benefit thousands of patients.
Lastly, other academic researchers will clearly derive impact from this research, which will provide them directly with new ideas and opportunities, and indirectly by increasing collaborative opportunities with one another and with the life sciences sector.
Patients with RA will derive the most immediate impact from our research, which could provide a novel therapy with a unique mechanism of action. This could result in better disease control, improved quality of life and reduced long-term complications, either as a monotherapy or in combination with existing drugs. Success will also stimulate research into related compounds from the same class as well as alternative anti-fibroblast drugs and targets (eg pro-apoptosis, epigenetic modifiers, anti-proliferative). It will also stimulate research into potential applications in other fibrotic diseases - all with potential downstream beneficial impact on patients. Via our Engagement programmes this work will have a wider impact on patients by reinforcing the benefits of participating in early phase experimental medicine research.
For similar reasons success will provide a boost to the UK life sciences industry. Clearly our Partner would benefit greatly but so too will other SMEs, biotechs, and pharma with alternative drugs from the same class, as well as drugs with the potential to target the fibroblast in a distinct manner. Our research would provide a novel target and a novel paradigm for the treatment of RA and would also trigger a re-analysis of exisiting compounds that may have therapeutic potential in RA or, indeed, other fibrotic diseases. RA remains a disease with a high unmet need and provides potentially high investment returns. Some of the other potential disease targets could become 'orphan' indications, with a more commercially favourable path to the clinic.
Downstream success will lead to a workforce with an improved skill set, including UK/EU contract manufacturing capabilities, and specialist PK testing. Ultimately successful development of a novel drug for RA will deliver substantial revenue to the UK and catalyse additional activity in the healthcare sector. It will also impact on HM Government by reinforcing the benefits of their investment in the life sciences industry.
We are using UK based companies for sub-contracted work. This will have a positive impact on income generated and jobs protected within home countries.
Because our research involves an orally available drug, it would likely be cheaper than the biologic drugs. If it substituted for them in the treatment pathway, or improved their efficacy as hypothesised, this would ultimately result in direct or indirect cost-savings to the NHS.
In addition to the MRC, Arthritis Research UK, NIHR, the Wellcome Trust, the partner Universities and NHS Trusts will benefit from our research, because they are providing some of the infrastructure and staff needed to perform this research. They would therefore be in a position to share in the success. The development of a new drug for RA would likely lead to an increase in charitable donations to relevant charities.
Success will impact on the project team both directly, via the experience and educational opportunities of performing a successful phase II experimental medicine study; and also indirectly from the emotional and psychological benefits of involvement with a study that could potentially benefit thousands of patients.
Lastly, other academic researchers will clearly derive impact from this research, which will provide them directly with new ideas and opportunities, and indirectly by increasing collaborative opportunities with one another and with the life sciences sector.
Organisations
- Newcastle University (Lead Research Organisation)
- University College London (Collaboration)
- University of Manchester (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- National Institute for Health Research (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Cardiff University (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- VERSUS ARTHRITIS (Collaboration)
- Cyclacel Ltd (Collaboration)
- UNIVERSITY OF LEEDS (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- UNIVERSITY OF SOUTHAMPTON (Collaboration)
- Cyclacel Pharmaceuticals (United Kingdom) (Project Partner)
Publications
Wong ZY
(2023)
Why does understanding the biology of fibroblasts in immunity really matter?
in PLoS biology
Siebert S
(2020)
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial.
in Medicine
Pratt AG
(2021)
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
in The Lancet. Rheumatology
Pratt Arthur G.
(2021)
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial
in LANCET RHEUMATOLOGY
Koliaraki V
(2022)
Mesenchymal cells in health and disease.
in Nature immunology
Mirza M
(2022)
Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology.
in Musculoskeletal care
McInnes IB
(2016)
Cytokines in rheumatoid arthritis - shaping the immunological landscape.
in Nature reviews. Rheumatology
Kearsley-Fleet L
(2018)
Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
in Annals of the rheumatic diseases
Description | A: Arthritis Research UK Disease Subcommittee Meeting, Chesterfield, 2018 |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
URL | https://www.versusarthritis.org/research/research-funding-and-policy/our-charitable-subcommittees/ |
Description | CONSORT-DEFINE and SPIRIT-DEFINE |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Contribution to new or improved professional practice |
URL | https://www.icr.ac.uk/DFCONSORT |
Description | DRFZ SAB |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://www.drfz.de/en/ |
Description | EULAR Consensus Meeting, Vienna, 2019 |
Geographic Reach | Europe |
Policy Influence Type | Membership of a guideline committee |
Impact | This committee generated guidance for the use of a new class of drugs in patients with rheumatic diseases. |
Description | MRC Translational Research Group London 2018 |
Geographic Reach | National |
Policy Influence Type | Membership of a guideline committee |
URL | https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group... |
Description | NIHR BRC Impact Showcase, Newcastle, 2018 |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Influential meeting on Healthy Ageing as a research priority of national importance, as exemplified by our NIHR BRC. |
URL | https://www.newcastlebrc.nihr.ac.uk/nihr-newcastle-biomedical-research-centre-impact-showcase-presen... |
Description | Novel Therapies in Rheumatoid Arthritis |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Wellcome Trust 4WARD Meeting 2016 - Clinical PhD Funding - Newcastle, Leeds, Manchester, Sheffield |
Geographic Reach | Local/Municipal/Regional |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | Consortium Clinical PhD Funding Meeting |
URL | http://www.4wardnorth.org.uk/ |
Description | NIHR Newcastle Biomedical Research Centre in Ageing and Long-term conditions |
Amount | £17,460,811 (GBP) |
Organisation | National Institute for Health Research |
Department | NIHR Biomedical Research Centre |
Sector | Public |
Country | United Kingdom |
Start | 04/2017 |
End | 03/2022 |
Description | NIHR Senior Investigator Award |
Amount | £360,000 (GBP) |
Funding ID | NIHR200224 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 04/2019 |
End | 03/2023 |
Description | Research into Inflammatory Arthritis Centre Versus Arthritis |
Amount | £1,999,997 (GBP) |
Funding ID | 22072 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2019 |
End | 03/2024 |
Description | A: RA Centre of Excellence - Birmingham Scientific Meeting. |
Organisation | University of Birmingham |
Department | Birmingham Clinical Trials Unit |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies. |
Collaborator Contribution | Equal partners with Glasgow and Birmingham. |
Impact | See additional awards and publications stemming from the RACE centre. |
Start Year | 2015 |
Description | A: RA Centre of Excellence - Birmingham Scientific Meeting. |
Organisation | University of Glasgow |
Department | Mental Health Rights Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies. |
Collaborator Contribution | Equal partners with Glasgow and Birmingham. |
Impact | See additional awards and publications stemming from the RACE centre. |
Start Year | 2015 |
Description | ARUK-NIHR Newcastle Experimental Arthritis Treatment Centre 2016 |
Organisation | Versus Arthritis |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Clinical, imaging, statistical and bioinformatics support. |
Collaborator Contribution | Infrastructure support including laboratory technical support, research nurses, project management, biostatistical and database management support. This has been crucial in tendering for other awards and trials. |
Impact | See Publications |
Start Year | 2012 |
Description | Cyclacel/TRAFIC |
Organisation | Cyclacel Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients |
Collaborator Contribution | Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements |
Impact | MRC DPFS/DCS grant for £1.1m |
Start Year | 2013 |
Description | Cyclacel/TRAFIC |
Organisation | University of Birmingham |
Department | Rheumatology Research Group |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients |
Collaborator Contribution | Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements |
Impact | MRC DPFS/DCS grant for £1.1m |
Start Year | 2013 |
Description | Cyclacel/TRAFIC |
Organisation | University of Glasgow |
Department | Department of Rheumatology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients |
Collaborator Contribution | Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements |
Impact | MRC DPFS/DCS grant for £1.1m |
Start Year | 2013 |
Description | RACE 2 |
Organisation | University of Birmingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are partners in this Centre of Excellence |
Collaborator Contribution | There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE |
Impact | None yet |
Start Year | 2019 |
Description | RACE 2 |
Organisation | University of Glasgow |
Department | School of Medicine Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are partners in this Centre of Excellence |
Collaborator Contribution | There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE |
Impact | None yet |
Start Year | 2019 |
Description | RACE 2 |
Organisation | University of Oxford |
Department | Kennedy Institute of Rheumatology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are partners in this Centre of Excellence |
Collaborator Contribution | There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE |
Impact | None yet |
Start Year | 2019 |
Description | RACE Scientific Meeting, Newcastle, 2018 |
Organisation | University of Birmingham |
Department | Birmingham University Imaging Centre (BUIC) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates. |
Collaborator Contribution | All contributed actively and gave valuable feedback. |
Impact | Scientific strategic planning outputs and plans for further collaboration. |
Start Year | 2015 |
Description | RACE Scientific Meeting, Newcastle, 2018 |
Organisation | University of Glasgow |
Department | Mental Health Rights Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates. |
Collaborator Contribution | All contributed actively and gave valuable feedback. |
Impact | Scientific strategic planning outputs and plans for further collaboration. |
Start Year | 2015 |
Description | RACE Scientific Meeting, Newcastle, 2018 |
Organisation | University of Oxford |
Department | Kennedy Institute of Rheumatology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates. |
Collaborator Contribution | All contributed actively and gave valuable feedback. |
Impact | Scientific strategic planning outputs and plans for further collaboration. |
Start Year | 2015 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | Cardiff University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | Imperial College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | National Institute for Health Research |
Country | United Kingdom |
Sector | Public |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | Queen Mary University of London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Birmingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Cambridge |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Leeds |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Manchester |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Nottingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | University of Southampton |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Description | Translational Research Collaboration for rheumatic and inflammatory diseases |
Organisation | Versus Arthritis |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Strategic Planning of experimental medicine studies. |
Collaborator Contribution | Strategic Planning of experimental medicine studies. |
Impact | A number of clinical trials have been completed and published |
Start Year | 2013 |
Title | TRAFIC:Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition |
Description | Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition ? - an early phase trial (TRAFIC): a non-randomised trial. Site set-up at three centres in the UK. Outsourcing of PK to Charles River and clinical trial packaging activities to third party. Part 1 (Identification of maximium tolerated dose by Continuous reassessment modelling completed October 2017. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2017 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Recruitment of two additional sites. First use of continuous reassessment modelling algorithm dose escalation study outside of oncology. |
URL | http://www.isrctn.com/ISRCTN36667085? |
Title | COLLABORATOR In-House Software |
Description | Software tool permitting continuous reassessment modelling algorithm to determine dose escalation allowing recruitment of patients to a complex trial across multiple collaborator sites. |
Type Of Technology | Webtool/Application |
Year Produced | 2017 |
Impact | May be of commercial interest. |
Description | "Bones" Exhibition at the Great North Museum 2017 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Workshops, demonstrations, talk, events and public information materials presented in parallel with the Bones Exhibition at the Great North Museum highlighting musculoskeletal research at our Centres of Excellence at Newcastle University including the Centre for Integrated Musculoskeletal Ageing, the Newcastle Experimental Arthritis Treatment Centre, the Rheumatoid Arthritis Centre of Excellence and the Newcastle Biomedical Research Centre. |
Year(s) Of Engagement Activity | 2017 |
URL | https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world |
Description | 4th International Workshop on Therapeutic Tolerancing |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Every 4 years Newcastle University hosts its international workshop on Clinical Therapeutic Tolerance. Previous editions covered 'Therapeutic Tolerance: Myth or Reality?' (2005), 'Therapeutic Tolerance: Closer to Reality?' (2009) and 'Therapeutic Tolerance: Tolerance Inducing Strategies in the Clinic'. (2013) Our fourth workshop carried the title 'Therapeutic Tolerance: First-in-Human Data' and was held from 27th - 30th June 2017. Main focus of the meeting was the analysis of data from the first therapeutic tolerance trials. The popular programme allows ample time for discussion and true debate, with an opportunity for poster presentations (with prizes). This international workshop is attended by leading scientists and practitioners in the field from around the world. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.newcastlebrc.nihr.ac.uk/news/therapeutic-tolerance-first-human-data-event/ |
Description | 9th International Symposium on Uveitis Dublin 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture on Biologics in Rheumatology |
Year(s) Of Engagement Activity | 2016 |
Description | ADARRC - RA Summit - Abu Dhabi |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The 7th annual Abu Dhabi Advanced Rheumatology Review Course provided a comprehensive update on adult and paediatric rheumatology. Designed as a three-day, intensive rheumatology course, ADARRC is a series of lectures and workshops delivered by global experts to provide new insights, case studies and pioneering research findings. |
Year(s) Of Engagement Activity | 2017 |
URL | http://adarrc.org/ |
Description | ARUK Arthritis Matters 2014 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | There was useful discussion after my presentation about the reach of charitable funding Patients volunteered to join TRAFIC steering group |
Year(s) Of Engagement Activity | 2014 |
URL | http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html |
Description | ARUK RACE Annual Meeting |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. We meet face to face three times per year. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.race-gbn.org/ |
Description | ARUK RACE Meeting - Glasgow |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.race-gbn.org/ |
Description | ARUK RACE Scientific Meeting - Birmingham |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.race-gbn.org/ |
Description | ARUK RACE Scientific Meeting - Newcastle |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.race-gbn.org/ |
Description | ARUK strategy meeting - Chesterfield |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | A meeting to update us on the charity (Arthritis Research UK), and particularly its recent merger with Arthritis Care. Also a useful discussion around future research directions. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.arthritisresearchuk.org/ |
Description | Amsterdam seminar and potential collaboration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Seminar - New concepts and novel targets in RA management, including DC therapy. Also met one-to-one with several potential collaborators; I anticipate this will lead to a collaboration around immune monitoring in AuToDeCRA 2. |
Year(s) Of Engagement Activity | 2019 |
URL | https://ams-rc.com/en/ |
Description | BSR Manipulating The Immune System - Birmingham |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | This was a lecture to rheumatologists in training on novel immunologically based therapies, at the annual BSR AGM. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.eiseverywhere.com/ehome/rheumatology2017/423982/ |
Description | Bones Exhibition Great North Museum 2017 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Design input to Learning Zone activities supporting the Exhibition. Posters and public information leaflets. |
Year(s) Of Engagement Activity | 2017 |
URL | https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world |
Description | Central & Eastern European Immunology Forum Bucharest 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | New Treatments for Immune Mediated Inflammatory Diseases |
Year(s) Of Engagement Activity | 2016 |
Description | Dutch Rheumatology Days |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Utrecht Rheumatology Workshop |
Year(s) Of Engagement Activity | 2016 |
Description | EULAR 2019 Organizing Committee |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Preparing for EULAR 2019 (Madrid). JDI is Abstracts Chair, a majpr role in the organising committee.. |
Year(s) Of Engagement Activity | 2018,2019 |
URL | https://www.congress.eular.org |
Description | EULAR AGM planning meeting, Zurich |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This is the committee that plans the annual scientific meeting for the European League Against Rheumatism. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.eular.org |
Description | EULAR Scientific Committee - Amsterdam |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This is the committee that plans the annual scientific meeting for the European League Against Rheumatism. I am the chair of this committee from 2018-2020. |
Year(s) Of Engagement Activity | 2018 |
URL | http://www.congress.eular.org/?utm_source=google&utm_medium=cpc&utm_campaign=registration&gclid=CjwK... |
Description | EULAR Scientific Programme Committee |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Planning meeting for EULAR 2019 in Madrid. As Abstract Chair I play a major role in this meeting. |
Year(s) Of Engagement Activity | 2018 |
URL | http://congress.eular.org/index.cfm |
Description | Faculty visit to Dublin |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | THis was an information exchange between FMS at Newcastle and the equivalent at Trinity, Dublin. I presented our immunology portfolio and they did the same. Others talked about ageing and neuroscience research Successful meeting. |
Year(s) Of Engagement Activity | 2019 |
Description | GSK Industry Engagement Visit Newcastle 2016 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Explored shared interests - potential for interaction - biopsy procedures |
Year(s) Of Engagement Activity | 2016 |
Description | Great North Experimental Arthritis Treatment Centre website |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Participants in your research and patient groups |
Results and Impact | The activity is ongoing |
Year(s) Of Engagement Activity | 2014 |
URL | http://www.greatneatcentre.com/ |
Description | International Forum for RA |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The International Forum for RA is a meeting focussed on cutting edge research in rheumatoid arthritis, with an emphasis on influencing future management strategies. I gave a presentation around 'smart trial designs'. This led to a new collaboration with Dana Orange (Rockefeller). |
Year(s) Of Engagement Activity | 2017 |
Description | J-TRC Meeting Q3 - London |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The NIHR Translational Research Collaboration for Joint and Related Inflammatory Diseases aims to assist industrial partners is early phase experimental medicine studies, by providing a national network of academic centres skilled in this type of research. Each meeting discusses opportunities, ongoing studies and general strategy. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-... |
Description | JTRP Steering Committee Meeting - London |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The NIHR Translational Research Collaboration for Joint and Related Inflammatory Diseases aims to assist industrial partners is early phase experimental medicine studies, by providing a national network of academic centres skilled in this type of research. Each meeting discusses opportunities, ongoing studies and general strategy. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-... |
Description | Joint Effort Support Group, Alnwick |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | I gave a presentation entitled Modern Management of Rheumatoid Arthritis - a Cure is in Sight, to a regional National Rheumatoid Arthritis Society group Well received, lots of questions |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.nras.org.uk/groups/joint-effort-group-alnwick |
Description | MRC DPFS Meeting - London |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including "repurposing" of existing therapies. Remit The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions. |
Year(s) Of Engagement Activity | 2018 |
URL | https://www.mrc.ac.uk/funding/browse/biomedical-catalyst-dpfs/biomedical-catalyst-developmental-path... |
Description | MRC Industrial Challenge Strategy Workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | This was a strategic planning meeting that informed the 2017/18 topics for the Industrial Strategy Challenge Fund call. |
Year(s) Of Engagement Activity | 2017 |
Description | MRC Research Strategy Visit 2016 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities. |
Year(s) Of Engagement Activity | 2016 |
Description | MRC TRG Meeting - London |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The MRC Translational Research Group (TRG) is responsible for ensuring strong continued support for translational research across the MRC. It supports translational research across MRC funding Boards and Panels, through partnerships with other funders and major Higher Education Institutions and through dedicated funding schemes. Areas of particular focus for TRG include: The Biomedical Catalyst, an integrated translational funding programme jointly operated with Innovate UK (formerly the Technology Strategy Board). The Confidence in Concept scheme, supporting academically led feasibility research at the institutional level. The Developmental Pathway Funding Scheme, part of the Biomedical Catalyst, supporting translation of fundamental discoveries toward benefits to human health. The Methodology Research Programme, in partnership with the National Institute for Health Research (NIHR). Coordination with the MRC-NIHR Efficacy and Mechanism Evaluation Programme (EME) programme and other NIHR funding schemes to ensure suitable projects progress to late-stage trials. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.mrc.ac.uk/about/our-structure/strategy-board-overview-groups/translational-research-grou... |
Description | NE Regional Meeting - Newcastle |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Regional Newcastle Meeting of Rheumatology Professionals, focussed on early rheumatoid arthritis and at risk individuals. I presented on tolerance-inducing strategies |
Year(s) Of Engagement Activity | 2017,2018 |
Description | NIHR BRC Impact Showcase, Newcastle, 2018 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Showcase event attended by senior figures from the Department of Health and major charities including Versus Arthritis. The CEOs of the Trust and University attended. Musculoskeletal presentations included patient presentations and videos. Ken Baker was awarded a prize for best oral presentation. Sir John Burn and Dame Jackie Daniel presented their vision for Newcastle. |
Year(s) Of Engagement Activity | 2018 |
URL | https://www.newcastlebrc.nihr.ac.uk/events/nihr-newcastle-biomedical-research-centre-impact-showcase... |
Description | NIHR Biomedical Research Centre Directors Meeting - London |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Discussions around expectations for the newly funded NIHR BRCs.. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/infrastructure/biomedical-research-... |
Description | Newcastle Upon Tyne Hospitals - Rheumatoid Arthritis Where Next? |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation on future RA research directions to junior doctors and medical staff in the NUTH Trust |
Year(s) Of Engagement Activity | 2016 |
Description | OK To Ask |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | Yes |
Geographic Reach | Regional |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Talks and poster sessions promoting participation in Newcastle Experimental Arthritis Treatment Centre. Generated questions, discussion and approaches from members of the public interested in participating in arthritis research. Patients contacted Research Nurses enquiring about participation in research. |
Year(s) Of Engagement Activity | 2015 |
URL | http://www.nihr.ac.uk/oktoask |
Description | Pfizer visit to Newcastle |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | A sizeable delegation of senior Pfizer personnel - scientific and business - visited for the day. They heard about our research, our electronic patient record, and the joint relationship between NHS and University - amongst other things. Pans were made for further interactions - which are now planned for Q2 2020. |
Year(s) Of Engagement Activity | 2019 |
Description | Plenary lecture and dinner at House of Commons - Ten Topics |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture - New Therapies, Future Cures. As part of this meeting i attended a speakers dinner at the House of Commons and spoke with a number of MPs about arthritis and our work. In particular I chatted over dinner with Estelle Morris, sec state for education 2001-02. |
Year(s) Of Engagement Activity | 2019 |
URL | http://www.tentopics.com/uploads/Topics-Programme-2019.pdf |
Description | Portuguese Society of Rheumatology - Algarve 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Keynote Lecture - New Treatments for IMID - invited paper to Annals Review |
Year(s) Of Engagement Activity | 2016 |
Description | RA Regional Meeting - Middlesbrough |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Sharing best practice around updates on the management of rheumatoid arthritis. |
Year(s) Of Engagement Activity | 2017 |
Description | RA Regional Meeting - Newcastle |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Sharing best practice and providing an update on novel approaches to RA management. |
Year(s) Of Engagement Activity | 2017 |
Description | RACE Annual Review 2016 Birmingham |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Annual review chaired by Ann Cooke. Caroline Aylott and Craig Bullock. Re-aligned research focus for 2016-2017. |
Year(s) Of Engagement Activity | 2016 |
Description | RACE Meeting Newcastle 2016 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Planning for the ARUK 'cure' call. |
Year(s) Of Engagement Activity | 2016 |
Description | RACE Scientific Advisory Board Meeting 2016 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Presentations on TRAFIC and BIO-FLARE as worked examples of our experimental medicine approach. |
Year(s) Of Engagement Activity | 2016 |
Description | RACE Scientific Meeting - Glasgow |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. This was the annual scientific meeting. |
Year(s) Of Engagement Activity | 2017 |
URL | http://www.race-gbn.org/ |
Description | RACE Scientific Meeting, Birmingham, 2018 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Scientific updates including progress with TRAFIC and BioFLARE. |
Year(s) Of Engagement Activity | 2018 |
Description | RACE Second International Scientific Advisory Board Meeting, Glasgow, 2018 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | Scientific presentations and patient-focused discussions. Excellent feedback from the panel, which has influenced.renewal plans. |
Year(s) Of Engagement Activity | 2018 |
URL | http://www.race-gbn.org/communityengagement/ |
Description | RACE launch |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Interesting discussions, including with an Olympian None yet |
Year(s) Of Engagement Activity | 2014 |
Description | Refractory Rheumatoid Arthritis - York 2016 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Keynote lecture on Refractory RA at the Northern group annual meeting |
Year(s) Of Engagement Activity | 2016 |
Description | Research Engagement Poster Campaign 2015 |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Poster campaign describing research in lay terms for public and patients audience. To promote engagement in research in the NE. Public and patients expressed interest in participating in research. |
Year(s) Of Engagement Activity | 2015 |
Description | Rheumatoid Arthritis Strategic Review, Newcastle, 2015 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Strategic realignment of research activities |
Year(s) Of Engagement Activity | 2015 |
Description | Rounds at Queen Mary Hospital, Hong Kong |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | During my trip to Hong Kong for the ICCR I visited Queen Mary Hospital where I discussed some complex cases and gave a seminar: Prevention of RA - pipedream or possibility? |
Year(s) Of Engagement Activity | 2019 |
URL | https://www8.ha.org.hk/qmh/ |
Description | South African Immunology Meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | University of Pretoria Basic Immunology and Immunology in RA. |
Year(s) Of Engagement Activity | 2016 |
Description | TEDx Newcastle |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | It provided an opportunity to highlight the importance of patient participation in experimental medicine and translational research studies The TEDx Newcastle website has received more than 10000 hits |
Year(s) Of Engagement Activity | 2014 |
URL | http://www.greatneatcentre.com/2014/07/the-patient-who-changed-my-life-people.html |
Description | Targeted Therapies Meeting - Mallorca 2016 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invite only meeting. Session chair. |
Year(s) Of Engagement Activity | 2016 |
Description | UK Autoimmunity Workshop - Defining the Grand Challenges - Clinical Trials, New Therapeutics, Repurposing |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | JDRF MRC ARUK WT |
Year(s) Of Engagement Activity | 2016 |
Description | Zing Conference Spain |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Prospective collaborations and partnerships |
Year(s) Of Engagement Activity | 2015 |
Description | seminar to rheumatologists St Gallen Switzerland |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited seminar - New concepts and novel targets in RA management to a mix of academic and non-academic Swiss rheumatologists. |
Year(s) Of Engagement Activity | 2019 |